TIGIT and neoplasm: Collectively, these findings support the coordinated expression of the TIGIT/PVR and PD-1/PD-L1 pathways in ESCC tumor tissues and identify high expression of TIGIT/PVR as a poor prognostic marker in patients with ESCC.